tradingkey.logo
搜尋

Takeda Pharmaceutical Co Ltd

TAK
添加自選
17.040USD
+0.220+1.31%
收盤 07-23 16:00美東報價延遲15分鐘
53.84B總市值
44.43本益比TTM

關於 Takeda Pharmaceutical Co Ltd 公司

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

Takeda Pharmaceutical Co Ltd簡介

公司代碼TAK
公司名稱Takeda Pharmaceutical Co Ltd
上市日期Jun 21, 2085
CEOWeber (Christophe)
員工數量47455
證券類型Depository Receipt
年結日Jun 21
公司地址4F
城市CHUO-KU
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Japan
郵編103-8668
電話81332782111
網址https://www.takeda.com/
公司代碼TAK
上市日期Jun 21, 2085
CEOWeber (Christophe)

Takeda Pharmaceutical Co Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--

常見問題

Takeda Pharmaceutical Co Ltd的前五大股東是誰?

Takeda Pharmaceutical Co Ltd的前五大股東如下:Dr. Steven H. (Steve) Gillis, Ph.D.

有多少機構持有Takeda Pharmaceutical Co Ltd(TAK)的股份?

截至2026Q1,共有637家機構持有Takeda Pharmaceutical Co Ltd的股份,合計持有的股份價值約為85.31M,占公司總股份的2.70% 。與2025Q4相比,機構持股有所增加,增幅為-8142483.00。

哪個業務部門對Takeda Pharmaceutical Co Ltd的收入貢獻最大?

在2026Q1,Gastrointestinal diseases業務部門對Takeda Pharmaceutical Co Ltd的收入貢獻最大,創收385.81B,占總收入的32.37% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有